After five years of unremitting efforts,the adult lymphoma team has caught the first wave of the era from chemotherapy to targeted and cellular immunotherapy.Based on current technologies and advantages,with precise integrated diagnosis as the cornerstone,the team established the Lymphoma and Myeloma Research Institute,expanded the specialty transplantation repository,adhered to innovation,faced challenges head-on,and continuously explored new treatment strategies for patients with refractory and relapsed diseases,committed to improving the cure rate of patients with refractory and relapsed lymphoma/multiple myeloma.

1.Daring to Explore,New Modes of Lymphoma Treatment

(1)CD7 CAR-T for R/R T-cell Lymphoma

The team applied CD7 CAR-T to the treatment of relapsed/refractory(R/R)T-cell lymphoma,achieving a 1-year overall survival(OS)rate of 65.5%and a progression-free survival(PFS)rate of 56.6%.The overall response rate(ORR)was 60%.

(2)Sequential CD19/20 CAR-T Cells"CAKE-ICING"for R/R DLBCL

The team's research found that sequential CD19/20 CAR-T cells"cake-icing"treatment for relapsed/refractory diffuse large B-cell lymphoma(R/R DLBCL)could induce lasting remission,with 36-month PFS and OS rates of 71.93%and 95.24%,respectively.

(3)Polatuzumab Vedotin Bridging to CD19CAR-T for R/R B-NHL

The team proposed new insights for a regimen based on the novel ADC drug Polatuzumab Vedotin as a bridge to CD19CAR-T treatment for relapsed/refractory B-cell lymphoma(R/R B-NHL).The study showed that the bridging cohort had significantly prolonged PFS and OS rates.

(4)Targeted Sequential Immunotherapy for R/R PMBCL

The team explored targeted sequential immunotherapy-PD-1 monoclonal antibody combined with chemotherapy as a debulking scheme bridging to CAR-T therapy for relapsed/refractory primary mediastinal large B-cell lymphoma(R/R PMBCL),showing promising results after bridging to CAR-T therapy.

(5)CAR-T for R/R B-NHL Achieving CR

The team found that for aggressive R/R B-NHL patients achieving complete remission(CR)after salvage chemotherapy,CAR-T combined with or without autologous stem cell transplantation(ASCT)as consolidation therapy is safe,with 1-year PFS and OS rates of 89%and 95%,respectively.Furthermore,combining CAR-T therapy with ASCT does not increase the risk of CRS or infection.

(6)CAR-T for Adult R/R BL

The team explored the efficacy of CAR-T therapy for adult relapsed/refractory Burkitt lymphoma(R/RBL),with ORR and CR rates of 31.6%and 21.1%respectively at 3 months post CAR-T cell infusion.

(7)ASCT Combined with CAR-T for R/R B-NHL

The team's research shows that ASCT combined with CAR-T therapy for advanced R/R B-NHL can achieve more durable remission in patients who were in remission before receiving ASCT combined with CAR-T cell therapy.

(8)CAR-T Cell Therapy Experience for Richter's Syndrome

The median overall survival(OS)for patients with Richter's syndrome(RT)is only 9-12 months.The team's exploration of CAR-T therapy for RT patients showed a 3-month CR rate of 56.3%,and ORR of 68.8%;with 1-year OS and PFS rates of 73.4%and 68.8%,respectively.

(9)Mini-TEDDi-R Scheme for SCNSL

Secondary central nervous system B-cell lymphoma(SCNSL)is an aggressive lymphoma with poor prognosis.The team used the mini-TEDDi-R regimen for patients with central nervous system involved DLBCL,achieving an ORR of 70.8%,CR rate of 58.3%,and good treatment tolerance.

2.Constantly Surpassing,New Strategies for Multiple Myeloma Treatment

BCMA CAR-T followed by allo-HSCT consolidation treatment for sPCL

The team found that BCMA CAR-T therapy could provide short-term remission for patients with secondary plasma cell leukemia(sPCL),with ORRs of 75%at 1 and 2 months post CAR-T,and 6-month PFS and OS rates of 62.5%and 60%respectively.It is recommended that patients achieving partial remission(PR)post CAR-T undergo allogeneic hematopoietic stem cell transplantation(allo-HSCT)consolidation treatment as soon as possible to achieve deep remission.

3.Never-Ending,New Directions for Benefit Enhancement

(1)Exploration of Immune Homeostasis at the Cellular Level in T-ALL/LBL with CD7 CAR-T Treatment

In collaboration with the team of Professor Yu Jian at the School of Medicine and Engineering,Beihang University,and the team of Associate Professor Chen Wei,it was for the first time elucidated that CD7-T cells after CD7 CAR-T treatment possess complete proliferative capability and immune function,revealing the dynamics of immune homeostasis at the cellular level in real patients undergoing CD7CAR-T treatment.This plays a very important role in clinical treatment decisions for relapsed/refractory T lymphoblastic leukemia/lymphoma(R/R T-ALL/LBL).

(2)CAR-T Cell Therapy Preparation from Frozen and Freshly Collected PBMCs for DLBCL

The team's research showed that frozen peripheral blood mononuclear cells(PBMCs)had no significant impact on the safety and efficacy of CD19 CAR-T treatment for patients with R/R DLBCL.These findings expand the treatment flexibility and accessibility of CD19 CAR-T therapy for DLBCL patients.

(3)Survival Prediction for Elderly B-NHL Patients Undergoing CAR-T Therapy

Research data indicates that the safety and efficacy of CAR-T cell therapy in patients over 70 years old are not significantly different from those aged 65-70 years.Elderly patients with an ADL score below 95 points have a lower survival rate post CAR-T therapy,especially those over 70 years old.